Peregrine Capital Management LLC Boosts Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Peregrine Capital Management LLC increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 64.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 66,140 shares of the company’s stock after buying an additional 25,814 shares during the period. Peregrine Capital Management LLC’s holdings in TransMedics Group were worth $4,124,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Venturi Wealth Management LLC lifted its holdings in TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares in the last quarter. National Bank of Canada FI lifted its holdings in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares in the last quarter. Quarry LP lifted its holdings in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after buying an additional 312 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after buying an additional 316 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its holdings in TransMedics Group by 3.8% during the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock worth $548,000 after buying an additional 322 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.00% of the stock is owned by company insiders.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $79.42 on Thursday. The company’s fifty day moving average price is $66.04 and its 200 day moving average price is $105.44. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.67 billion, a P/E ratio of 84.49 and a beta of 2.12.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Piper Sandler reduced their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Robert W. Baird reduced their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.